Retrospective study of total neoadjuvant therapy for locally advanced rectal cancer.
Yutian ZhaoJiahao ZhuBo YangQizhong GaoYu XuXianding WeiDong KongShengjun JiBojian FeiPublished in: Future oncology (London, England) (2021)
Aim: To compare treatment outcomes of total neoadjuvant therapy (TNT) and the standard treatment for locally advanced rectal cancer (LARC). Materials & methods: Patients with LARC (cT2-4 and/or cN1-2) who were treated with preoperative chemoradiotherapy plus induction and consolidation chemotherapy followed by surgery or the standard treatment were recruited. Pathologic complete response (pCR) rate, overall survival, disease-free survival and the sphincter preservation rate as well as safety were evaluated. Results: 49 cases were treated with TNT and 71 cases received the standard treatment. Multivariate analysis demonstrated that TNT and tumor size were independent risk factors for pCR. Grade 3 chemoradiotherapy toxicity and postoperative complications were similar between the two groups. Conclusion: TNT improved the pCR rate for patients with LARC, with tolerable toxicities.
Keyphrases
- rectal cancer
- locally advanced
- neoadjuvant chemotherapy
- free survival
- squamous cell carcinoma
- radiation therapy
- lymph node
- minimally invasive
- computed tomography
- stem cells
- coronary artery disease
- patients undergoing
- magnetic resonance imaging
- magnetic resonance
- combination therapy
- newly diagnosed
- image quality
- data analysis
- smoking cessation
- surgical site infection
- dual energy